search indicatorNeed Help? Search Tools

Books by Subject

Drug Therapy

  • Nursing Process Guidelines -- Patient Safety and Medication Administration -- Pharmacologic Classes -- Alphabetical Listing of Drugs by Generic Name.
  • ABC Transporters and Cancer provides invaluable information on the exciting and fast-moving field of cancer research. Here, outstanding and original reviews are presented on a variety of topics. This volume covers ABC transporters and cancer, and is suitable for researchers and students alike.
  • This book summarizes how the renin angiotensin system is implicated in the progression of atherosclerotic disease as well as of left ventricular dysfunction and reviews the action of angiotensin converting enzyme inhibitors and AT1 receptor antagonists on reducing morbidity and mortality in patients with left ventricular dysfunction or in those at high cardiovascular risk with preserved ventricular function. ACEi and ARBS in Hypertension and Heart Failure is a highly practical reference reviewing the evidence and providing a rationale for the appropriate use of RAS antagonists in cardiovascular diseases. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.
  • Poor adherence to therapy is one of the main obstacles to treatment effectiveness in schizophrenia. It is the main determinant of relapse, hospitalization, symptom persistence, and poor psychosocial functioning and outcome. Adherence to treatment is affected by various factors related to the disease characteristics, to the patient him- or herself, to the treatment, and to the therapeutic relationship. Some of these factors are modifiable, and both pharmacological and non-pharmacological strategies have been developed for this purpose.This book addresses the different aspects of adherence to treatment in schizophrenia and related disorders in a systematic but easy-to-use manual format. Chapters focus on a full range of issues, including pharmacological and non-pharmacological strategies to enhance adherence and continuity of care, relevant psychological factors, the importance of the patient-doctor relationship, and the need for an alliance with other care-givers. Adherence to Antipsychotics in Schizophrenia will be an invaluable asset for all who are involved in the care of patients with schizophrenia.
  • Also available: Print – 2005
  • Advances in antiepileptic drug development / Philip N. Patsalos -- Current guidelines and standard treatments / Dieter Schmidt & G{uml}unter Kr{uml}amer -- Advances in screening models for identifying new antiepileptic drugs / Kinga K. Borowicz & Stanislaw J. Czuczwar -- New antiepileptic drugs : advances in pharmacokinetics, drug interaction and adverse effect profiles / Domenico Italiano & Edoardo Spina -- Antiepileptic drugs in clinical trials and future direction / Alberto Verrotti, Chiara Cirillo & Giulia Loiacono.
  • "The skin is one of the most frequently involved organs in adverse drug reactions. Occurring with an incidence of 1 to 5 percent for certain types of drugs, cutaneous drug eruptions are mostly benign in nature, and comprise the maculopapular type of eruption and urticaria. However, about one third of them require hospital treatment, leading to a considerable burden for the health care system. In this book, a selected group of experts provide an up-to-date, condensed and clinically relevant overview of the field of cutaneous drug eruptions, ranging from epidemiology and genetic predisposition to available therapeutic measures, including rapid drug desensitization. Reflecting the great progress made in recent years in this field, this publication will be a useful tool for a better understanding, diagnosis and management of cutaneous drug eruptions, not only for general physicians, dermatologists and clinical allergologists, but also for nurses and scientists." -- publisher's site.
  • Pt. 1. Target organ toxicity. -- Drug-induced liver injury / Michael Holt, Cynthia Ju.-- Drug herpersensitivity reactions involving skin / Oliver Hausmann, Benno Schnyder, Werner J. Pichler.-- Adverse drug reactions affecting blood cells / Richard H. Aster.-- Molecular mechanisms of adverse drug reactions in cardiac tissue / Reza Tabrizchi.-- Mechanisms of drug-induced nephrotoxicity / Thomas D. Nolin, Jonathan Himmelfarb.-- Receptor- and reactive intermediate-mediated mechanisms of teratogenesis / Peter G. Wells, Crystal J.J. Lee, Gordon P. McCallum, Julia Perstin, Patricia A. Harper.-- Pt. II. Mediators/Biochemical pathways.-- Role of reactive metabolites in drug-induced hepatotoxicity / A.M. Srivastava, J. L. Maggs, D. J. Antoine, D. P. Williams, D. A. Smith, B. K. Park.-- Role of cytokines in the mechanism of adverse drug reactions / Mary Jane Masson, Lindsay A. Collins, Lance R. Poh.-- Keap1-Nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity / Ian M. Copple, Christopher E. Goldring, Neil R. Kitteringham, B. Kevin Park.-- Signal transduction pathways involved in drug-induced liver injury / Derick Han, Mie Shinohara, Maria D. Ybanez, Behnam Saberi, Neil Kaplowitz.-- Mictrochondrial involvement in drug-induced liver injury / Dominique Pessayre, Abdellah Mansouri, Alain Berson, Bernard Fromenty.-- Pt. III. Examples/Models.-- Mechanisms of acetaminophen-induced liver necrosis / Jack A. Hinson, Dean W. Roberts, Laura P. James.-- Drug-induced liver injury in humans: the case of Ximelagtran / M. Keisu, T.B. Andersson.-- Troglitazone / Tsuyoshi Yokoi.-- Neviropine hypersensitivity / M. Popovic, J.M. Shenton, J. Chen, A. Baban, T. Tharmanathan, B. Mannargudi, D. Abdulla, J.P. Uetrecht.-- Mechanisms of adverse drug reactions to biologics / Janet B. Clarke.-- Pt. IV. Risk factors/Screening drug candidates.-- Pharmacogenetics of idiosyncratic adverse drug reactions / Munir Pirmohamed.-- Danger hypothesis applied to idiosyncratic drug reactions / Jinze Li, Jack P. Uetrecht.-- Approaches for minimizing metabolic activation of new drug candidates in drug discovery / Sanjeev Kumar, Kaushik Mitra, Kelem Kassahun, Thomas A. Baillie.
  • AIDS therapy. 3rd ed. 2008
    AIDS treatments continues to evolve. Now, so does the definitive reference on this complex and challenging subject. "AIDS Therapy, 3rd Edition" not only brings you comprehensive guidance on the latest treatments for HIV/AIDS and the full range of related disorders and syndromes, but also comes with access to updates online--so you can always tap into the most current therapy guidelines. Written by a "who's who" of leading global experts, the new edition of this classic reference is a must for any clinician who manages patients with HIV/AIDS. The most comprehensive coverage available on AIDS treatment equips you to meet any clinical challenge. Contributions from a large cast of noted international authorities put global "best practices" at your fingertips. Advice from some of the most respected experts in the field helps you manage your patients confidently.
  • The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system differently and is expressed continually over time. Essentially, radiation and chemotherapy are intense biologic modifiers that allow for cancer cure and cancer survivorship but accelerate senescence of normal tissues and increase the incidence of age-related diseases and second malignant tumors. Volume 2 of this two-volume work comprehensively documents potential late effects in all the normal tissue anatomic sites in the human body. The detection, diagnosis, management and prevention of effects are all considered in detail, and prognostic outcomes are discussed. Radiation risk factors and interactions with chemotherapy effects are clearly presented. The text is accompanied by numerous supportive illustrations and tables.
  • Analgesia 2007
    Part I. Introduction -- Peripheral and central mechanism of pain generation / H.G. Schaible -- Part II. Drugs in clinical use -- Opioids / C. Zöllner, C. Stein -- Antipyretic analgesics: nonsteroidal antiinflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolionones / B. Hinz, K. Brune -- Local anesthetics / R. Yanagidate, G.R. Strichartz -- Serotonin receptor ligands: treatments of acute migraine and cluster headache / P.J. Goadsby -- Anti-convulsants and anti-depressants / A.H. Dickenson, J. Ghandehari -- Part III. Compounds in preclinical development -- Neuropeptide and kinin antagonists / R. G. Hill, K.R. Oliver -- Glutamate receptor ligands / V. Neugebauer -- Adrenergic and cholinergic compounds / R. D. Sanders, M. Maze -- Cannabinoids and pain / I.J. Lever, A.S.C. Rice -- Part IV. Future targets in analgesia research -- Adenosine and ATP receptors / J. Sawynok -- Ion channels in analgesia research / J.N. Wood -- Protein kinases as potential targets for the treatment of pathological pain / R. R. Ji, Y. Kawasaki, Z. Y. Zhuang, Y.R. Wen, Y.Q. Zhang -- Part V. Pain Management beyond pharmacotherapy -- Placebo and endogenous mechanisms of analgesia / F. Bededetti -- Limitations of pharmacotherapy: behavioral approaches to chronic pain / H. Flor, M. Diers -- Subject index.
  • 1. Historical introduction -- 2. Modes of action -- 3. The problem of resistance -- 4. Pharmacodynamics of anti-infective agents: target delineation and susceptibility breakpoint selection -- 5. Antimicrobial agents and the kidneys -- 6. Drug interactions involving anti-infective agents -- 7. Antibiotics and the immune system -- 8. General principles of antimicrobial chemotherapy -- 9. Laboratory control of antimicrobial therapy -- 10. Principles of chemop rophylaxis -- 11. Antibiotic policies -- 12. Aminoglycosides and aminocyclitols -- 13. β-Lactam antibiotics : cephalosporins -- 14. β-Lactam antibiotics: penicillins -- 15. Other β-lactam antibiotics -- 16. Chloramphenicol and thiamphenicol -- 17. Diaminopyrimidines -- 18. Fosfomycin and fosmidomycin -- 19. Fusidanes -- 20. Glycopeptides -- 21. Lincosamides -- 22. Macrolides -- 23. Mupirocin -- 24. Nitroimidazoles -- 25. Oxazolidinones -- 26. Quinolones -- 27. Rifamycins -- 28. Streptogramins -- 29. Sulfonamides -- 30. Tetracyclines -- 31. Miscellaneous antibacterial agents -- 32. Antifungal agents -- 33. Antimycobacterial agents -- 34. Anthelmintics -- 35. Antiprotozoal agents -- 36. Antiretroviral agents -- 37. Other antiviral agents -- 38. Sepsis -- 39. Abdominal and other surgical infections -- 40. Infections associated with neutropenia and transplantation -- 41. Infections in intensive care patients -- 42. Infections associated with implanted medical devices -- 43. Antiretroviral therapy for HIV -- 44. Infections of the upper respiratory tract -- 45. Infections of the lower respiratory tract -- 46. Endocarditis -- 47. Infections of the gastrointestinal tract -- 48. Hepatitis -- 49. Skin and soft-tissue infections -- 50. Bacterial infections of the central nervous system -- 51. Viral infections of the central nervous system -- 52. Bone and joint infections -- 53. Infections of the eye -- 54. Urinary tract infections -- 55. Infections in pregnancy -- 56. Sexually transmitted diseases -- 57. Leprosy -- 58. Tuberculosis and other mycobacterial infections -- 59. Superficial and mucocutaneous mycoses -- 60. Systemic fungal infections -- 61. Zoonoses -- 62. Malaria -- 63. Other protozoal infections -- 64. Helminthic infections.
  • Antibody-drug conjugates 2013
    Springer Protocols
    Antibody-drug conjugate (ADC) clinical pipeline : a review / Ingrid Sassoon and Veronique Blanc -- Antibody-drug conjugate target selection : critical factors / Neil H. Bander -- Selecting an optimal antibody for antibody-drug conjugate therapy : internalization and intracellular localization / Jay Harper ... [et al.] -- Antibody-drug conjugate payloads / Jan Anderl ... [et al.] -- Linker technologies for antibody-drug conjugates / Birte Nolting -- In vivo testing of drug-linker stability / Pierre-Yves Abecassis and Celine Amara -- Pharmacokinetics and ADME characterizations of antibody-drug conjugates / Kedan Lin, Jay Tibbitts, and Ben-Quan Shen -- Safe handling of cytotoxic compounds in a biopharmaceutical environment / Miriam I. Hensgen and Bernhard Stump -- Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting / James E. Stefano ... [et al.] -- Protocols for lysine conjugation / Marie-Priscille Brun and Laurence Gauzy-Lazo -- Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers / Sunil Bhakta, Helga Raab, and Jagath R. Junutula -- Enzymatic antibody modification by bacterial transglutaminase / Patrick Dennler, Roger Schibli, and Eliane Fischer -- Formulation development of antibody-drug conjugates / William J. Galush and Aditya A. Wakankar -- Conjugation process development and scale-up / Bernhard Stump and Jessica Steinmann -- Methods for conjugating antibodies to nanocarriers / Anil Wagh and Benedict Law -- Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy / Yan Chen -- Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography / Jun Ouyang -- Drug-to-antibody ratio (DAR) and drug load distribution by LC-ESI-MS / Louisette Basa -- Determination of charge heterogeneity and level of unconjugated antibody by imaged cIEF / Joyce Lin and Alexandru C. Lazar -- Risk-based scientific approach for determination of extractables/leachables from biomanufacturing of antibody-drug conjugates (ADCs) / Weibing Ding.
  • This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
  • The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
  • Susceptibility testing methods of antifungal agents / Erika J. Ernst -- Deoxyribonucleic acid fingerprinting methods for Candida species / Shawn R. Lockhart ... [et al.] -- CARE-2 fingerprinting of Candida albicans isolates / Joachim Morschhäuser, Peter Staib, and Gerwald Köhler -- Targeted gene deletion in Candida albicans wild-type strains by MPAR flipping / Joachim Morschhäuser, Peter Staib, and Gerwald Köhler -- Application of Deoxyribonucleic acid microarray analysis to the study of azole antifungal resistance in Candida albicans / Katherine S. Barker and P. David Rogers -- Application of proteomic analysis to the study of azole antifungal resistance in Candida albicans / Massoumeh Z. Hooshdaran, George M. Hilliard, and P. David Rogers -- Techniques for antifungal susceptibility testing of Candida albicans biofilms / Gordon Ramage and Josʹe Luis Lʹopez-Ribot -- Natural products and antifungal drug discovery / Melissa R. Jacob and Larry A. Walker -- Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy / David Andes -- Murine model of invasive aspergillosis / Russell E. Lewis and Nathan P. Wiederhold -- Antifungal combinations / Roxana G. Vitale, Javier Afeltra, and Eric Dannaoui -- Post-antifungal effect methods / Roxana G. Vitale -- Evaluation of immunotherapy in invasive candidiasis: antifungal activity and cytokine expression assays / Maria Simitsopoulou and Emmanuel Roilides -- Interaction of histoplasma capsulatum with human macrophages, dendritic cells, and neutrophils / Simon L. Newman -- Immunology of infection caused by cryptococcus neoformans / Floyd L. Wormley, Jr. and John R. Perfect.
  • Pt. 1. General properties of antimicrobial agents -- Pt. 2. Resistance to antimicrobial agents -- Pt. 3. General principles of usage of antimicrobial agents -- Pt. 4. Therapeutic use of antimicrobial agents.
  • Antiplatelet agents 2012
    Part 1. Pathophysiology. Platelets: Production, Morphology and Ultrastructure / Jonathan N. Thon and Joseph E. Italiano -- Platelet Receptors / Alexandre Kauskot and Marc F. Hoylaerts -- Platelet Signaling / Timothy J. Stalker, Debra K. Newman, Peisong Ma, Kenneth M. Wannemacher and Lawrence F. Brass -- Platelet Interaction with the Vessel Wall / Philip G. de Groot, Rolf T. Urbanus and Mark Roest -- Platelets in Atherosclerosis and Thrombosis / Christian Schulz and Steffen Massberg -- Part 2. Pharmacology. Aspirin and Other COX-1 Inhibitors / Carlo Patrono and Bianca Rocca -- Thienopyridines and Other ADP-Receptor Antagonists / Isabell Bernlochner and Dirk Sibbing -- Glycoprotein IIb/IIIa Antagonists / Karen M. Hook and Joel S. Bennett -- Targeting Phosphodiesterases in Anti-platelet Therapy / Matthew T. Rondina and Andrew S. Weyrich -- PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis / Sergio Leonardi and Richard C. Becker -- Thromboxane Receptors Antagonists and/or Synthase Inhibitors / Giovanni Davì, Francesca Santilli and Natale Vazzana -- Inhibitors of the Interaction Between von Willebrand Factor and Platelet GPIb/IX/V / Paolo Gresele and Stefania Momi -- Inhibitors of the Interactions Between Collagen and Its Receptors on Platelets / Hans Deckmyn, Simon F. De Meyer, Katleen Broos and Karen Vanhoorelbeke -- Intracellular Signaling as a Potential Target for Antiplatelet Therapy / Patrick Andre -- Novel Targets for Platelet Inhibition / Kathleen Freson and Chris Van Geet -- Variability of Platelet Indices and Function: Acquired and Genetic Factors / Giovanni de Gaetano, Iolanda Santimone, Francesco Gianfagna, Licia Iacoviello and Chiara Cerletti -- Small RNAs as Potential Platelet Therapeutics / Leonard C. Edelstein and Paul F. Bray -- Pharmacological Modulation of the Inflammatory Actions of Platelets / Richard Amison, Clive Page and Simon Pitchford -- Part 3. Therapy. The Role of Laboratory Monitoring in Antiplatelet Therapy / Marco Cattaneo -- Antiplatelet Agents in Ischemic Heart Disease / Christopher H. May and A. Michael Lincoff -- Antiplatelet Therapy in Cerebrovascular Disorders / Ralph Weber, Johannes Brenck and Hans-Christoph Diener -- Antiplatelet Therapy in Peripheral Artery Disease / Francesco Violi, Stefania Basili, Jeffrey S. Berger and William R. Hiatt -- Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents / Tom Mead.
  • Antiplatelet Agents: Current and Novel -- Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring -- Anticoagulant Drugs: Current and Novel -- Antithrombotic Treatment of Cardiovascular Disease -- Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease.
  • Antisense therapeutics. 2nd ed. 2005
    Springer Protocols
    Antisense therapeutics: a promise waiting to be fulfilled / M. Ian Phillips -- Antisense inhibition: oligonucleotides, ribozymes and siRNAs / Y. Clare Zhang ... [et al.] -- Local application of antisense for prevention of restenosis / Patrick L. Iversen ... [et al.] -- Antisense therapeutics for hypertension: targeting the renin-angiotensin system / M. Ian Phillips and Birgitta Kimura -- Antisense strategies for the treatment of heart failure / Sian E. Harding, Federica del Monte, and Roger J. Hajjar -- Clinical studies of antisense oligonucleotides for cancer therapy / Rosanne M. Orr and F. Andrew Dorr -- Antisense therapy in clinical oncology: preclinical and clinical experiences / Ingo Tamm -- Radionucleide-peptide nucleic acid diagnosis and treatment of pancreatic cancer / Eric Wickstrom ... [et al.] -- Suppression of pancreatic and colon cancer cells by antisense K-ras RNA expression vectors / Kazunori Aoki, Shumpei Ohnami, and Teruhiko Yoshida -- Induction of tumor cell apoptosis and chemosensitization by antisense strategies / Manuel Rieber and Mary Strasberg-Rieber -- Utility of an anti-oncogene ribozymes and antisense oligonucletoides in reversing drug resistance / Tadao Funato -- Transport of antisense across the blood-brain barrier / Laura B. Jaeger and William A. Banks -- Transdermal delivery of antisense oligonucletoides / Rhonda M. Brand and Patrick L. Iversen -- Antisense strategies for redirection of drug metabolism: using paclitaxel as a model / Vikram Arora -- Antisense oligonucletoide treatment of inflammatory bowel diseases / Bruce R. Yacyshyn -- Optimizing electroporation conditions for the intracellular delivery of morpholino antisense oligonucleotides directed against the hepatitis C virus internal ribosome entry site / Ronald Jubin.
  • The paradigm for atrial fibrillation (AF) management has changed significantly in recent years. A new era has begun for the prevention of one of the most tremendous complication of AF, stroke. Prevention of ischemic stroke in AF patients with oral anticoagulants represents a huge challenge because of the narrow therapeutic change of these drugs, interindividual and intraindividual variability, and the unsatisfactory time in therapeutically range (TTR) with this type of medication.
  • Also available: Print – 2008
    Microbial drug resistance: a historical perspective / William C. Summers -- Ecology of antibiotic resistance genes / Abigail A. Salyers, Nadja Shoemaker, and David Schlesinger -- Global response systems that confer resistance / Paul F. Miller and Philip N. Rather -- Multidrug efflux pumps: structure, mechanism, and inhibition / Olga Lomovskaya ... [et al.] -- Mechanisms of aminoglycoside antibiotic resistance / Gerard D. Wright -- Resistance to [beta]-lactam antibiotics mediated by [beta]-lactamases : structure, mechanism, and evolution / Jooyoung Cha, Lakshmi P. Kotra, and Shahriar Mobashery -- Target modification as a mechanism of antimicrobial resistance / David C. Hooper -- Antibiotic permeability / Harry Taber -- Genetic methods for detecting bacterial resistance genes / Ad C. Fluit -- Evolution and epidemiology of antibiotic-resistant pneumococci / Christopher Gerard Dowson and Krzysztof Trzcinski -- Antimicrobial resistance in the enterococcus / George M. Eliopoulos -- Methicillin resistance in staphylococcus aureus / Keeta S. Gilmore, Michael S. Gilmore, and Daniel F. Sahm -- Mechanism of drug resistance in mycobacterium tuberculosis / Alex S. Pym and Stewart T. Cole -- Antibiotic resistance in enterobacteria / Nafsika H. Georgopapadakou -- Resistance as a worldwide problem / Paul Shears -- Public health responses to antimicrobial resistance in outpatient and inpatient settings / Cindy R. Friedman and Arjun Srinivasan -- Antibacterial drug discovery in the 21st century / Steven J. Projan.
  • The emergence of bioinformatics : historical perspective, quick overview and future trends / Christos A. Ouzounis -- The statistical design and interpretation of microarray experiments / Kevin K. Dobbin and Richard M. Simon -- Whole-genome analysis of cancer / Steven A. Enkemann ... [et al.] -- Bioinformatics approaches to the analysis of the transcriptome of animal models of cancer / Mark J. Hoenerhoff ... [et al.] -- Significance of aberrant expression of miRNAs in cancer cells / George A. Calin ... [et al.] -- Proteomic methods in cancer research / Scot Weinberger and Egisto Boschetti -- Comprehensive genomic profiling for biomarker discovery for cancer detection, diagnostics and prognostics / Xiaofeng Zhou ... [et al.] -- Gene expression profiling of the leukemias : oncogenesis, drug responsiveness, and prediction of clinical outcome / Lars Bullinger, Hartmut Dohner, and Jonathon R. Pollack -- Personalized medicine in the clinical management of colorectal cancer / Anthony El-Khoueiry and Heinz Josef Lenz -- PIK3CA gene alterations in human cancers / Sérgia Velho, Carla Oliveira, and Raquel Seruca.
  • Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
  • This book provides an authoritative overview of botulinum neurotoxin (BoNT) treatment menus for 14 pain categories with an evidence based literature review on each pain disorder, illustrative figures along with brief video clips showing the techniques and patient interviews. Introductory chapters cover basic information about the mechanism, function and the analgesic effects of the BoNTs based on the data derived from animal studies. Clinical chapters define pain in conditions such as post-herpetic and post-traumatic neuralgias, plantar fasciitis, low back pain, post-surgical pain syndromes and migraine in detail, provide discussion of current modes of treatment and updated information on BoNT therapy. Each chapter also includes illustrative case histories. Botulinum Toxin Treatment of Pain Disorders will prove an invaluable resource for clinicians and researchers involved in the treatment of pain disorders including neurologists, pain medicine specialists, anesthesiologists, internists, those conducting research in pharmacology and toxicology as well as students in these areas.
  • Also available: Print – 2010
  • Print Material
  • Mechanism of action of topoisomerase I poisons / Leroy F. Liu and Shyamal D. Desai -- Crystallographic insight into the mechanism of drug-induced topoisomerase I DNA damage / Alex B. Burgin, Jr., Bart L. Staker, and Lance Stewart -- Inhibitors of topoisomerase I function / Sidney M. Hecht -- Cytotoxic mechanisms of the topoisomerase I inhibitors / Yves Pommier ... [et al.] -- Biochemical and genetic analyses of DNA topoisomerase I-mediated DNA damage / Robert C.A.M. Van Waardenburg and Mary-Ann Bjornsti -- Preclinical models for evaluating topoisomerase-I targeted drugs / Aarti S. Juvekar ... [et al.] -- Mechanisms of resistance to camptothecins / Zeshaan A. Rasheed and Eric H. Rubin -- Recent advances in camptothecin drug design and delivery strategies / Thomas G. Burke ... [et al.] -- Clinical experience with 9-aminocamptothecin: lessons for new drug development / Chris H. Takimoto -- Clinical studies of rubitecan (9-nitro 20(s) camptothecin) / Hilary Hewes, Judith A. Smith, and Claire Verschraegen -- Irinotecan: current clinical status and pharmacological aspects / Laurent P. Rivory -- Clinical experience with topotecan / Aimee K. Bence and Val R. Adams -- The clinical development of lurtotecan: experience with water-soluble and liposomal forms / Keith T. Flaherty ... [et al.] -- Preclinical and clinical development of dx-8951f (exatecan mesylate): a hexacyclic camptothecin analog / Eric K. Rowinsky -- Camptothecins in the treatment of primary brain tumors / Clinton F. Stewart, Markos Leggas, and Henry S. Friedman -- Camptothecins in the treatment of lung cancer / Pankaj Kumar ... [et al.] -- Use of camptothecins in the treatment of leukemia and related disorders / Bejamin M.F. Mow and Scott H. Kaufmann.
  • Clinical strategies for cancer treatment: the role of drugs / Bruce Chabner -- Preclinical aspects of cancer drug discovery and development / Paula Krosky ... [et al.] -- Pharmacokinetics / Jerry Collins, Jeffrey G. Supko -- Infertility after cancer chemotherapy / Angela Bradbury, Richard L. Schilsky -- Carcinogenesis of anticancer drugs / Laawrence S. Blaszkowsky, Charles Erlichman -- Antifolates / Brian P. Monahan, Carmen J. Allegra -- 5-Fluoropyrimidine / Jean L. Grem -- Cytidine analogues / David P. Ryan, Rocio Garcia-Carbonero, Bruce A. Chabner -- Purine antimetabolites / Kenneth R. Hande -- Hydroxyurea / Luis Paz-Ares, Ross C. Donehower, Bruce A. Chabner -- Antimicrotubule agents / Eric K. Rowinsky -- Clinical and high-dose alkylating agents / Kenneth D. Tew, O. Michael Colvin, Roy B. Jones -- Nonclassic agents / Henry S. Friedman, Steven D. Averbuch, Joanne Kurtzberg -- Cisplatin, Carboplatin, and oxaliplatin / Eddie Reed -- Bleomycin / John s. Lazo, Bruce A. Chabner -- Antitumor antibiotics / Edwin W. Willems, Kees Nooter, Jaap Verweij -- Topoisomerase I-targeting drugs / Alex Sparreboom, William C. Zamboni -- Anthracyclines and anthracenediones / James H. Doroshow -- Topoisomerase II inhibitors: the epipodophyllotoxins, acridines, and ellipticines / Yves Pommier, François Goldwasser -- Asparaginase / Bruce A. Chabner, Alison M. Friedmann -- Delivering anticancer drugs to brain tumors / Maciej M. Mrugala, Tracy T. Batchelor, Jeffrey G. Supko -- Food and drug administration role in oncology product development / Thomas G. Roberts Jr. -- Central venous catheters: care and complications / Rachel P. Rosovsky, David J. Kuter -- Pharmacogenetics / Jeanne Fourie, Robert B. Diasio -- New targets for anticancer therapeutics / A. Dimitrios Colevas ... [et al.] -- Bisphosphonates / Matthew R. Smith -- Thalidomide and its analogs for the treatment of hematologic malignancies, including multiple myeloma, and solid tumors / Paul Richardson ... [et al.] -- Inhibitors of tumor angiogenesis / Anaadriana Zakarija, William J. Gradishar -- Proteasome inhibitors / Owen A. O'Connor -- Molecular targeted drugs and growth factor receptor inhibitors / Jeffrey W. Clark -- Antibody therapies of cancer / David A. Scheinberg ... [et al.] -- Interferons / Daniel J. Lindner ... [et al.] -- Adoptive cellular therapies / Carl H. June -- Cancer vaccines / Glenn Dranoff -- Hematopoietic growth factors / William P. Petros -- Interleukins / Gheath Alatrash ... [et al.] -- Harmonal therapy for breast cancer / Peter F. Lebowitz, Sandra M. Swain.
  • Clinical strategies for cancer treatment: the role of drugs -- Target identification and drug discovery -- Clinical drug development and marketing approval -- Principles of pharmacokinetics -- Delivering anticancer drugs to brain tumors -- Pharmacogenetics -- Physical barriers to drug delivery -- Antifolates -- 5-fluoropyrimidines -- Cytidine analogues -- Purine antimetabolites -- Hydroxyurea -- Antimitotic drugs -- Alkylating agents -- Platinum analogues -- Bleomycin and other antitumor antibiotics -- Topoisomerase I-targeting drugs -- Topoisomerase II inhibitors: anthracyclines -- Topoisomerase II inhibitors: the epipodophyllotoxins -- Asparaginase -- Proteasome inhibitors -- Histone deacetylase inhibitors in oncology -- Differentiating agents -- Arsenic trioxide -- Antibodies -- Inhibitors of tumor angiogenesis -- Epidermal growth factor receptor inhibitors -- HER2 inhibitors -- Molecular targeted drugs -- Signaling inhibitors: IGFR, PI3K pathway, embryonic signaling inhibitors, and mitotic kinase inhibitors -- Cytokine therapy for cancer -- Cancer vaccines -- Adoptive cellular therapies -- Thalidomide and its analogs in the treatment of hematologic malignancies, including multiple myeloma, and solid tumors -- Hormonal therapy of breast cancer -- Hormone therapy for prostate cancer -- Drug therapy of pain in cancer patients -- Hematopoietic growth factors -- Antinausea medications -- Bisphosphonates and other bone-targeted therapies -- Intravenous access and catheter management -- Late effects of cancer chemotherapy -- Infertility after cancer chemotherapy.
  • A simple introduction explaining the broad principles underlying chemotherapy, this book gives trainees a framework within which they can place the specific aspects of cancer chemotherapy they encounter in their everyday experience. The first part of this book is unique in explaining the recent developments in the field in terms of their point of action in the natural history of cancer. The second and third sections contain a more straightforward description of practical aspects of chemotherapy, and the current place of drug treatment in everyday cancer management, including the outcomes of that treatment.
  • Also available: Print – 2006
  • Also available: Print – 2007
  • This book is an essential guide to the medical treatment of the cardiac patient and presents core principles of cardiovascular therapeutics as well as drug recommendations. Major classes of drugs are featured, including beta-blockers, ACE inhibitors, calcium antagonists, diuretics, and antiplatelet agents and unique insights into the controversies surrounding the use of specific drugs are explored, with answers given to the question: do beta blockers and diuretics really cause diabetes? Properties, dosage, side effects, potential salutary benefits, and drawbacks on virtually all commercially available cardiac drugs are examined. This revised edition is thoroughly updated and addresses the entire spectrum of heart disorders, such as hypertension, angina, myocardial infarction, heart failure, arrhythmias, cardiac arrest, and dyslipidemias. New chapters include endocrine heart diseases, management of cardiomyopathies, and newer agents. In addition, topics such as cardiac drugs in pregnancy and lactation and drug interactions are covered. Cardiac Drug Therapy, Eighth Edition, is an authoritative and clinically relevant resource for cardiologists, cardiology fellows, and internists.
  • In the western world, the risk of cardiovascular disease in pregnancy has grown due to the increasing age at the first pregnancy and the worldwide obesity epidemic leading to early diabetes and hypertension. As a result more women are requiring drug therapy during pregnancy and some data has shown an altered pharmacodynamic profile in pregnant women when compared to the non-pregnant population. Cardiac Drugs in Pregnancy presents up-to-date research for the treatment of cardiovascular disease during pregnancy, and discusses the most important indications of drug usage in pregnancy and postpartum. The book aims to assess the potential risk of drugs and their possible benefit against each other, making it an essential read for a wide range of health professionals involved in cardiac drug therapy in pregnancy.
  • 1. GRB2 Signaling as a Molecular Target for Cancer / Alessio Giubellino -- 2. Human Arylamine N-acetyltransferase 1: From Drug Metabolism to Drug Target / Fernando Rodrigues-Lima, Julien Dairou, Florent Busi, and Jean-Marie Dupret -- 3. Targeting Argininosuccinate Synthetase in Cancer Therapy / Niramol Savaraj, Min You, Chunjing Wu, Macus Tien Kuo, Vy Dinh, Medhi Wangpaichitr, and Lynn Feun -- 4. Parathyroid Hormone-Related Peptide Signaling in Cancer / Franco Oreste Ranelletti and Giovanni Monego -- 5. Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma / Francesco Piazza and Gianpietro Semenzato -- 6. Role of Bile Acids in Carcinogenesis of Gastrointestinal Tract / Hiroshi Yasuda and Fumio Itoh -- 7. AIB1: A Transcriptional Coactivator Which Integrates Signaling Cross Talk in Cancer Cells / Macarena Ferrero and Jaime Font de Mora -- 8. Rational Design of DNA Anticancer Agent That Targets Signal Transducer and Activator of Transcription 3 (Stat3) for Cancer Therapy / Naijie Jing -- 9. Estrogen Receptor Signaling in Lung Cancer / P.A. Hershberger and J.M. Siegfried -- 10. Microparticle Dissemination of Biological Activities: Implications for Cancer Biology / Pauline P. Goh -- 11. Protein Kinase D Signaling in Cancer / Peter Storz -- 12. Cell Signaling and Cancer: Integrated, Fundamental Approach Involving Electron Transfer, Reactive Oxygen Species, and Antioxidants / Peter Kovacic and Ratnasamy Somanathan -- 13. Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy / Fabio P.S. Santos, Inbal Hazan-Halevy, and Zeev Estrov.
  • 1. Circuitry of Checkpoint Response -- Evasion of G1 Checkpoints in Cancer -- Distinct Pathways Involved in S-Phase Checkpoint Control -- Mechanisms of G2 Phase Arrest in DNA Damage-Induced Checkpoint Response -- 2. Checkpoint Response and the Aetiology of Cancer -- Chromatin Modifications and Orchestration of Checkpoint Response in Cancer -- DNA Damage Response and the Balance Between Cell Survival and Cell Death -- Dysfunction of the RB Retinoblastoma Gene in Cancer -- G1 Phase Cyclins in Cancer Development and Progression -- The BRCA1/2 Pathway Prevents Some Leukemias and Lymphomas in Addition to Breast/Ovarian Cancers: Malignancies that Overcome Checkpoint Controls -- 3. Targeting Checkpoint Response in Cancer Therapy -- Regulation of p53 Activity and Associated Checkpoint Controls -- The Importance of p53 Signaling in the Response of Cells to Checkpoint Inhibitors -- Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy -- p27Kip1 as a Biomarker and Target for Treatment of Cancer -- Targeting Cyclin-Dependent Kinases with Small Molecule Inhibitors -- Chk1 and Chk2 as Checkpoint Targets -- Targeting Cdc25 Phosphatases in Cancer Therapy.
  • Also available: Print – 2010
    Short introduction and history / Robert B. Raffa -- Patient's perspective / Robert B. Raffa and Kathy Martin -- Oncology nurse's perspective / Jamie S. Myers -- Oncology pharmacist's perspective / Rachel Clark-Vetri -- The impact of chemo brain on the patient with a high grade glioma / Michele R. Lucas -- Oncology pharmacist's perspective / Rachel Clark-Vetri -- The impact of chemo brain on the patient with a high grade glioma / Michele R. Lucas -- Neurocognitive effects of childhood cancer treatment / Jennifer Costa -- The economic burden / Albert I. Wertheimer -- Designing conceptual model-based research in chemotherapy-related changes in cognitive function / Lisa M. Hess -- Neuropsychologic testing for chemotherapy-related cognitive impairment / Jamie S. Myers -- Imaging as a means of studying chemotherapy-related cognitive impairment / Robert B. Raffa -- Chemotherapy associated central nervous system damage / Jørg Dietrich -- Is systemic anti-cancer therapy neurotoxic? Does chemo brain exist? And should we rename it? / Sophie Taillibert -- Evaluation of multiple neurotoxic outcomes in cancer chemotherapy / Bernard Weiss -- Chemotherapy-related visual system toxicity / Robert B. Raffa -- The possible role of cytokines in chemotherapy-induced cognitive deficits / Jamie S. Myers -- Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy / Swati Nagar -- Combination analysis / Ronald J. Tallarida -- Animal models / Ellen A. Walker -- Chemo brain (chemo fog) as a potential side effect of doxorubicin administration : role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction / Christopher D. Aluise ... [et al.] -- Effects of 5-FU / Peter M. Wigmore ... [et al.] -- Future directions / Robert B. Raffa and Ronald J. Tallarida.
  • Use of psychotropic drugs has come to dominate clinical practice in psychiatry worldwide--perhaps owing largely to perceived simplicity, ease of use, and apparent efficiency, as well as apparent cost-effectiveness of such treatments. Nevertheless, medicinal treatments for patients with psychiatric disorders are but one component of comprehensive clinical care of complex human problems. Extensively updated since its second edition in 1985, Chemotherapy in Psychiatry, Third Edition, again addresses basic aspects of modern psychopharmacology and clinical applications of drugs used in the treatment of major psychiatric disorders, with major emphasis on psychotic, bipolar, and depressive disorders. The presentation covers descriptions of the main classes of psychotropic drugs, selected information concerning their known action mechanisms and metabolic disposition, and their clinical applications for acute illnesses and to prevent recurrences and long-term morbidity. Also covered are limitations and adverse effects of each type of agent, with emphasis on the fact that all psychotropic medicines have adverse effects that range from annoying to potentially lethal. Chemotherapy in Psychiatry, Third Edition, outlines the need to balance benefits and risks at the level of individual persons. Authoritative, and an important contribution to the literature, Chemotherapy in Psychiatry, Third Edition is an invaluable resource for physicians, scientists, trainees, and policymakers.
  • Scientific basis of cancer chemotherapy -- Norton-simon hypothesis -- Drug resistance -- Principles of chemotherapy -- Clinical trials -- Hematopoietic growth factors -- Biologic response modifiers: principles of biotherapy -- Intraventricular and intrathecal therapy -- Intraperitoneal chemotherapy -- Continuous intravenous infusion chemotherapy -- Intraarterial chemotherapy -- Isolated regional therapy -- Hematopoietic stem cell transplantation -- Oral toxicity -- Dermatologic toxicity -- Extravasation -- Hypersensitivity reactions -- Ocular side effects of chemotherapy -- Cardiotoxicity of cancer therapy -- Pulmonary toxicity of antineoplastic therapy -- Gastrointestinal complications of chemotherapy -- Hepatotoxicity of chemotherapeutic agents -- Renal and electrolyte abnormalities due to chemotherapy -- Chemotherapy-induced peripheral neuropathy -- Vascular toxicity of antineoplastic agents -- Second malignancies after chemotherapy -- Chemotherapy in pregnancy -- Gonadal complications and teratogenicity of cancer therapy -- Central venous access for chemotherapy -- Systemic therapy for advanced melanoma -- General issues in brain tumor chemotherapy -- Chemotherapy of head and neck cancer -- Chemotherapy of lung cancer -- Breast cancer -- Gastrointestinal cancer -- Endocrine tumors -- Chemotherapy of genitourinary cancers -- Chemotherapy of gynecologic cancers -- Chemotherapy of carcinoma of unknown primary site -- Chemotherapy of bone and soft tissue sarcomas -- Chemotherapy for pediatric solid tumors -- Chemotherapy of hodgkin's lymphoma -- Non-hodgkin's lymphoma -- Acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia -- Chemotherapy of the myelodysplastic syndromes -- Management of myeloproliferative disorders and chronic myeloid leukemia -- Chemotherapy of multiple myeloma and other plasma cell disorders.
  • "Written for Pain Management Practitioners, Oncologists, Oncology Nurses, Nurse Practitioners, Social Workers, Pharmacologists, and Primary Care Practitioners, as well as students in these fields, this reference provides insight into chemotherapy-induced neuropathic pain cancer survivors suffer. It reviews the basic and clinical research into the normal physiology of pain transmission pathways, neuropathic pain pathology, the chemotherapeutic drug mechanisms of action and adverse effects, chemotherapy-induced neuropathy, and drug discovery efforts for treatment. Bridging the gap between theory and practice, this reference covers both basic science and clinical research, providing a unique insight into drug discovery efforts"--Provided by publisher.
  • The Cleveland Clinic Manual of Headache Therapy is a hands-on, practical guide to diagnosis, work-up, and treatment of common headache disorders. Each chapter is written by a Cleveland Clinic Headache Center care provider. The book uses an evidence-based approach to sift through the wealth of available data and identify the most appropriate treatments. This manual is aimed at practicing neurologists and pain specialists, fellows and residents, and also primary care physicians. The Cleveland Clinic Manual is the most trusted source on this ever expanding and developing topic.
  • Print Material
    This edition has been retitled Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications to reflect the increasing body of knowledge linking the two concepts that explain the relationship between drug administration and drug response and also reflects the expansion in our understanding at the molecular and mechanistic levels of all the processes controlling the pharmacokinetics of drugs.
  • Carbamazepine -- Felbamate -- Gabapentin -- Lamotrigine -- Levetiracetam -- Oxcarbazepine -- Phenobarbital, primidone -- Phenytoin -- Pregabalin -- Tiagabine -- Topiramate -- Valproic -- Zonisamide.
  • Molecular biology of colon cancer / William M. Grady -- Chemoprevention of colorectal cancer / Yu-Ning Wong ...[et al.] -- Colorectal cancer screening and surveillance / Arnold J. Markowitz -- Cytotoxic chemotherapy for metastatic colorectal cancer / M. Wasif Saif, Richard Kim, and Edward Chu -- Integration of antiangiogenic strategies in colorectal cancer treatment / John M. Strother and Charles D. Blanke -- The role of EGFR inhibition in colorectal cancer / Nabeel Shalan and Paulo M. Hoff -- Second-line strategies in the treatment of patients with metastatic colorectal cancer / Anthony B. El-Khoueiry and Heinz-Josef Lenz -- Adjuvant chemotherapy for colon cancer / Bert H. O'Neil ... [et al.] -- Management of locally advanced rectal cancer / Yu Jo Chua and David Cunningham -- Rationale for adjuvant and neoadjuvant chemotherapy in the resection of liver metastases / Axel Grothey and Steven A. Alberts -- Percutaneous radiofrequency ablation in the management of patients with colorectal cancer / Karen Brown -- Colorectal cancer imaging / Sean D. Curran and Laurence H. Schwartz -- Nursing issues in colorectal cancer chemotherapy / Ellen Hollywood and Deborah Semple -- Pain management in the colorectal cancer patient / Vivek Tim Malhotra -- Novel agents and new paradigms for colorectal cancer / Chris Takimoto and Russell Kruzelock.
  • Targeting of the EGFR as a modulator of cancer chemotherapy / Jose Baselga -- Cyclin dependent kinase inhibitors in combination chemotherapy / Manish A. Shah and Gary K. Schwartz -- Development of protein kinase C and cyclin-dependent kinase inhibitors as potentiators of cytotoxic drug action in leukemia / Steven Grant -- Carboxyamidotriazole, an inhibitor of nonvoltage operated calcium entry : single agent and combination therapy for ovarian carcinoma / Chad M. Michener and Elise C. Kohn -- Targeted alpha particle therapy : a rational approach to drug development in hematologic diseases and solid tumors / John M. Burke, David A. Scheinberg, and Joseph G. Jurcic -- Pharmacologic modulation of fluoropyrimidines : building upon the lessons of the past / Owen A. O'Connor -- Development of inhibitors of HER2 with taxanes : new directions in breast cancer therapy / Shanu Modi, Monica N. Fornier, and Andrew D. Seidman -- Targeting nf-b to increase the activity of cisplatin in solid tumors / Don S. Dizon ... [et al.] -- Combinations of chemotherapy and G3139, an antisense BCL-2 oligonucleotide / Luba Benimetskaya, Sridhar Nami, and C. A. Stein -- Use of animal models to evaluate signal transduction inhibitors as modulators of cytotoxic therapy / Beverly A. Teicher.
  • Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
  • Also available: Print – 2013
  • v. 1. Global perspective / volume editor, Peter D. Kennewell -- v. 2. Strategy and drug research / volume editor, Walter H. Moos -- v. 3. Drug discovery technologies / volume editor, Hugo Kubinyi -- v. 4. Computer-assisted drug design / volume editor, Jonathan S. Mason -- v. 5. ADME-Tox approaches / volume editors, Bernard Testa and Han van de Waterbeemd -- v. 6. Therapeutics areas I: central nervous system, pain, metabolic syndrome, urology, gastrointestinal and cardiovascular / volume editor, Michael Williams -- v. 7. Therapeutic areas II: cancer, infectious diseases, inflammation & immunology and dermatology / volume editors, Jacob J. Plattner & Manoj C. Desai -- v. 8. Case histories and cumulative subject index / volume editors, John B. Taylor & David J. Triggle.
  • The pace of new research and level of innovation repeatedly introduced into the field of drug delivery to the lung is surprising given its state of maturity since the introduction of the pressurized metered dose inhaler over a half a century ago. It is clear that our understanding of pulmonary drug delivery has now evolved to the point that inhalation aerosols can be controlled both spatially and temporally to optimize their biological effects. These abilities include controlling lung deposition, by adopting formulation strategies or device technologies, and controlling drug uptake and release.
  • Classification of the Antibiotics -- Antibiotics Marketed in the EU -- Principles of Antibiotic Therapy -- The Most Common Errors in Antibiotic Therapy -- Important Infections and Their Microbiological Diagnosis -- Cooperation with Microbiologists -- Resistance of Major Clinical Pathogens -- The Most Frequent Pathogens- Choice of Antibiotics -- Antibiotics, Antimycotics: Spectrum- Dosage- Adverse Effects- Costs -- Antibiotic Therapy of the Principal Infections in Children and Adults -- Treatment of the Most Frequent Types of Bacterial Endocarditis -- Minimal Duration of Treatment for Bacterial Infections -- Failure of Antibiotic Therapy -- Fever of Unknown Origin: Differential Diagnosis -- Dosage of Antibiotics in Impaired Renal Function -- Antibiotic Therapy in Haemodialysis, Peritoneal Dialysis, and Continuous Haemofiltration -- Antibiotic Therapy During Pregnancy and Lactation -- Antibiotics in Liver Diseases -- Diffusion of Antibiotics in Cerebrospinal Fluid and in Cerebral Abscesses -- Local Antibiotics -- Prophylactic Antibiotic Therapy -- Physical Incompatibility of Antibiotics and Antimycotics in Infusion Solutions -- Useful Websites.
  • Print Material
  • Print Material
  • "Novel drug delivery technologies strive to bypass challenging biological layers to elicit desired pharmacological activity. The skin, one of our key defensive barriers, is imperfect, and may allow certain topically applied substances or toxins to pass. The dermatokinetics of a drug determines the efficacy of treatment of skin disorders. Presenting the first comprehensive reference on this important area of research, Dermatokinetics of Therapeutic Agents includes a general overview of the theoretical as well as practical aspects of dermatokinetics and addresses the impact of nature of a drug delivery system on the dermatokinetics of drugs. Chapters and illustrations cover the introductory aspects significance, methods, and models used in dermatokinetic studies of therapeutic agents.Topics include: Theoretical Models for Dermatokinetics of Therapeutic Agents; Drug Delivery Approaches to Modulate Dermatokinetics of Drugs; Conventional Methods of Cutaneous Drug Sampling; Cutaneous Microdialysis; Sampling Substrates by Skin Permeabilization; Spectroscopic Techniques in Dermatokinetics Studies; Regulatory Perspective of Dermatokinetic Studies"--Provided by publisher.
  • The pharmacokinetic basis of therapeutics -- The pharmacodynamic basis of therapeutics -- Adverse reactions and drug-drug interactions -- Herb-drug interactions -- Food-drug interactions.
  • "Reduced production of DHEA associated with the diseases that accompany aging has led to its use as a nutritional supplement for antiaging, metabolic support, and other purposes. While animal studies have clearly shown substantial benefits of DHEA in combating various disease states, the effect of low levels of DHEA in humans is less established, and the mechanisms of action and potential involvement in illnesses remain unclear. DHEA in Human Health and Aging reviews the past ten years of research into this hormone and explores its potential for future study."--Publisher's description.
  • 2012 ClinicalKey
    Introduction and overview of current targets: bench to clinic / Mark R. Kelley -- 2. MGMT a critical DNA repair gene target for chemotherapy resistance / Stanton L. Gerson and Lili Liu -- 3. Blockade of base excision repair: inhibition of small lesions results in big consequences to cancer cells / Melissa Fishel and Carlo Vascotto -- 4. PARP inhibitors -- scientific rationale and clinical development for cancer / Ruth Plummer, Nicola J. Curtin and Yvette Drew -- 5. Inhibiting selective DNA polymerases for therapeutic intervention / Anthony J. Berdis -- 6. Targeting the nucleotide excision repair pathway for therapeutic applications / John Turchi and Stephan M. Patrick -- 7. Homologous recombination and ATM/ATR targets / Henning Willers, Lee Zou and Heike N. Pfaffle -- 8. DNA double strand break repair by nonhomologous end joining and its clinical relevance / Michael Weinfeld and Susan Lees-Miller -- 9. Defective MMR-c-Abl-p73-GADD45alpha expression in cancer chemoresistance / David Boothman and Long Shan Li -- 10. DNA repair signaling targets / Susan Ashwell -- 11. Redox regulation of DNA repair and therapeutic / Millie M. Georgiadis -- 12. Personalized cancer medicine: DNA repair alterations is a promising predictive marker in cancer / Srinivasan Madhusudan -- 13. The role of DNA damage and repair in neurotoxicity caused by cancer therapies / Michael R. Vasko -- 14. Future directions with DNA repair inhibitors / Mark R. Kelley.
  • "Drug delivery technologies represent a vast and vital area of research and development in pharmaceutics. The demand for innovative drug delivery systems continues to grow, and this growth drives a variety of new developments. Building on the foundation provided by the second edition, Drug Delivery Systems, Third Edition covers the latest in research, development, and regulations in industry and academia.The third edition of this popular book provides a comprehensive review of the latest research and development on drug delivery systems (including liposomal, transmucosal, transdermal, oral, polymeric, and monoclonal antibody directed delivery); it also contains a new chapter on nanoscience and technology for drug delivery along with cutting-edge business intelligence and strategies. These topics are spread into five sections: Site-specific drug delivery Polymers and implantable drug delivery systems Oral drug delivery Transdermal, transmucosal, ocular, and miscellaneous drug delivery systems Regulatory considerations and global outlook Written in a straightforward, clear, and concise manner, the authors provide a global perspective on current and future advances and market opportunities. The book answers the need for comprehensive information in a single resource for anyone venturing into this area of drug development and who desires an overview of the field, with extensive guidance on where to gain more information. Each chapter provides a table of marketed and investigational products, with numerous practical examples; the book also provides readers with a multitude of possible drug delivery systems that can be used to improve therapeutics, along with global and regulatory perspectives"--Provided by publisher.
  • 1. Drug evaluations in pancreatic cancer culture systems -- 2. Mouse xenograft models for drug discovery in pancreatic cancer -- 3. Flourescent metastatic mouse models of pancreatic cancer for drug discovery -- 4. A new preclinical paradigm for pancreas cancer -- 5. Zebrafish as a biological system for identifying and validating therapeutic targets and compounds -- 6. Gene expression arrays in pancreatic cancer drug discovery research -- 7. Using array comparative genomic hybridization of pancreatic cancer samples to map interesting regions for target gene identification -- 8. The application of high-throughput RNAi in pancreatic cancer target discovery and drug development -- 9. MicroRNA a profiling and its application in drug discovery in pancreatic cancer -- 10. Methylation detection and epigenomics in pancreatic cancer -- 11. Tissue microarray applications in drug discovery for pancreatic cancer -- 12. Proteomic analysis of blood and pancreatic juice -- 13. Applications of antibody-lectin sandwich arrays (ALSA) to pancreatic cancer diagnostics and drug discovery -- 14. The development of pharmacodynamic endpoint models for evaluation of therapeutic in pancreatic cancer -- Index.
  • Print Material
    Drug products alphabetically organized and cross-referenced by U.S. and Canadian brand names and index terms; information on brand names, usage, dosage, pregnancy considerations, warnings, adverse reactions, and drug interactions.
  • Print Material
    Presents alphabetically arranged entries of drug products providing information on brand names, usage, dosage, pregnancy considerations, warnings, adverse reactions, and drug interactions.
  • 1. Introduction to Drug Interactions / Keith Gallicano and George Drusano -- 2. Mechanisms of Drug Interactions 1: Absorption, Metabolism, and Excretion / Angela D. M. Kashuba and Joseph S. Bertino, Jr. -- 3. Mechanisms of Drug Interactions 2: Transport Proteins / Scott R. Penzak -- 4. A Regulatory Perspective on Drug Interactions / Kellie Reynolds -- 5. Drug Interactions With Antiretrovirals for HIV Infection / Kimberly A. Struble and Stephen C. Piscitelli -- 6. Drugs for HIV-Related Opportunistic Infections / Alice Tseng -- 7. Drugs for Tuberculosis / Rocsanna Namdar, Steven C. Ebert, and Charles A. Peloquin -- 8. Quinolones / David R. P. Guay -- 9. β-Lactam Antibiotics / Melinda M. Neuhauser and Larry H. Danziger -- 10. Antifungal Agents / Paul O. Gubbins, Scott A. McConnell, and Jarrett R. Amsden -- 11. Miscellaneous Antibiotics / Gregory M. Susla -- 12. Drug-Food Interactions / Kelly A. Harris, Kevin W. Garey, and Keith A. Rodvold -- 13. Drug-Cytokine Interactions / Curtis E. Haas and Jamie L. Nelsen -- 14. Circumventing Drug Interactions / Douglas N. Fish -- 15. Design and Data Analysis of Drug Interaction Studies / David E. Nix and Keith Gallicano -- Index.
  • Introduction to Drug-Drug Interactions -- Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion -- Mechanisms of Drug Interactions II: Transport Proteins -- Drug-Food Interactions -- Interactions Between Herbs and Antiinfective Medications -- Drug-Cytokine Interactions -- Beta-Lactam Antibiotics -- Macrolides, Azalides, and Ketolides -- Quinolones -- Glycopeptides, Lipopeptides, and Lipoglycopeptides -- Miscellaneous Antibiotics -- Drugs for Tuberculosis -- Drug Interactions with Antiretrovirals for HIV Infection -- Non-HIV Antiviral Agents -- Antifungal Agents -- Antimalarial Agents -- Antiprotozoal and Anthelmintic Agents -- Drug Interaction Considerations Throughout Drug Development -- Probe Cocktail Studies -- Design and Data Analysis in Drug Interaction Studies.
  • With people aged 65 years and older currently making up the fastest growing age group throughout the world, the demographic revolution of an aging society will inevitably lead to increased pressure to develop a rationalistic and age-tailored process of diagnosis and treatment among the elderly. As aging people often suffer from several chronic diseases and are being treated with multiple medications concurrently, unwanted drug interactions occur more frequently. Whereas recent approaches have recommended to remove particular drugs from the medication regimen to avoid adverse effects, Drug Therapy for the Elderly underlines both indispensable and dispensable elements of drug treatment, providing the practitioner with:- Background information on the elderly population regarding their needs for particular drugs (with an eye to frailty, co-morbidity patterns, and special sensitivities regarding drug metabolism and excretion)- Practical advice about drug treatment surveillance parameters in the elderly- In-depth discussion of drugs in relation to the elderly with specific diagnoses- Integration of multimorbidity/polypharmacy situations into prioritization schemes- A plan for how to deal with the complexity of polypharmacy situations in a five-minute consultationAn original classification of drugs is proposed by the editor which relates the power of effects, prognostic data, and tolerability to a prioritization scoring system. This approach is the first to not only provide a negative listing, but also integrates positive data into an overall assessment for drugs fit for the aged. Therefore, Drug Therapy for the Elderly serves as a timely reference for a wide array of physicians.
  • This Adis Pocket Reference presents an up-to-date, succinct, and practical approach to drug therapy for type 2 diabetes.
  • Print Material
  • Drug-eluting stents 2012
    Future Med
    Drug-eluting stents / Imad Sheiban & Fabrizio D'Ascenzo -- Drug-eluting stents : overview and indications / Fabrizio D'Ascenzo & Imad Sheiban -- Coronary artery stents : approved first-generation drug-eluting stents / Jason R. Foerst, Frank Gruenheck, Malte Kelm & Marc Vorpahl -- Approved drug-eluting stents : second generation / Giampaolo Niccoli & Gregory A. Sgueglia -- Drug-eluting stents in development / Joanne Shannon & Azeem Latib -- Current guidelines for the use of drug-eluting stents / Gill Louise Buchanan & Alaide Chieffo -- Index.
  • Print Material
  • Male sexual health -- Structure and physiology of the testis -- Introduction -- The spermatozoa -- Sperm motility -- Capacitation and acrosome reaction -- Fertilization of the oocyte -- Testing substances that compromise spermatogenesis and fertility (adapted from Creasy 1997) -- Testosterone production and testosterone effects -- Physiology of erection -- Introduction -- Role of androgens in erection -- Priapism -- Physiology of ejaculation -- Drugs which compromise male sexual health -- Adverse drug effects -- Male sexual health and drugs -- Drugs which compromise testicular function -- Drugs which compromise erectile function -- Drugs which compromise ejaculation -- Database of drugs.
  • General commentary on drug therapy and drug risks in pregnancy / Richard K. Miller, Paul W. Peters, and Christoff E. Schaefer -- Specific drug therapies during pregnancy / Mimke Reuvers and Christof Schaefer -- General commentary on drug therapy and drug risk during lactation / Ruth Lawrence and Christof Schaefer -- Specific drug therapies during lactation / Chistof Schaefer and Ruth Lawrence.
  • "Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting."
  • Also available: Print – 2008
  • Also available: Print – 2005

Access restricted to Stanford community

Shortcut to Licensed Content

Lane Gateway to Licensed Content

TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.

What is it?

Lane Gateway to Licensed Content

Bookmark on Other Websites

Bookmark on Lane

  • TO INSTALL, RIGHT CLICK this button.
  • Select "Add to Favorites" (click “Continue” if you see a security alert)
  • From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
  • Once installed it will look like this
  • Click "Bookmark on Lane" to bookmark any webpage
  • Your saved bookmark will appear on this page

What is it?

A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more. Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available. Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences. Includes cited reference searching, citation maps, and an analyze tool.Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not. Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities. In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines. Over 10,000 notes outline the status of specific infections within each country.
Large number of high quality software and database programming titles from O'Reilly. Other software titles are also available from Sams and Prentice Hall. Limited to 7 concurrent users.Vast collection of software and database programming titles from multiple publishers, including Microsoft Press.Largest provider of engineering-related eBooks; includes titles in computer science and biomedical engineering.Over 4,000 full-text e-books covering scientific and technical information from CRC Press and others. Many handbooks and single volume reference sources.Includes peer-reviewed life science and biomedical research protocols compiled from Methods in Molecular Biology, Methods in Molecular Medicine, Methods in Biotechnology, Methods in Pharmacology and Toxicology, Neuromethods, the Biomethods Handbook, the Proteomics Handbook, and Springer Laboratory Manuals.Contains full text access to selected biomedical and nursing books.Provides online, full-text access to Springer's journal titles as well as journals from other publishers. Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.